Log on/register
BioMed Central home | Journals A-Z | Feedback | Support | My details
 
Open AccessHighly AccessResearch

Anti-HER-2 engineering antibody ChA21 inhibits growth and induces apoptosis of SK-OV-3 cells

AnLi Zhang1* email, Hua Xue1* email, XiaoGuang Ling1 email, Yi Gao1 email, Feng Yang1 email, LianSheng Cheng2 email, Jing Liu2 email and Qiang Wu1 email

Department of Pathology, Anhui Medical University, 69# Meishan Road, Hefei, Anhui, 230032, PR China

School of Life Science, University of Science and Technology of China, Hefei, 230027, PR China

author email corresponding author email* Contributed equally

Journal of Experimental & Clinical Cancer Research 2010, 29:23doi:10.1186/1756-9966-29-23

Published: 10 March 2010

Abstract

Background and Aims

Anti-HER-2 antibodies targeting distinct epitopes have different biological functions on cancer cells. In a previous study, we demonstrated that anti-HER-2 engineering antibody ChA21 was able to bind to subdomain I of HER-2 extracellular domain. In this study, The effects of ChA21 on growth and apoptosis against ovarian carcinoma cell SK-OV-3 over-expressing HER-2 in vitro and in vivo were investigated.

Methods

Cell growth inhibition was evaluated by MTT assay. Apoptosis was detected by TUNEL stain, transmission electron microscopy and flow cytometry on cultured cells and tissue sections from nude mice xenografts. The apoptosis-related proteins Bax and Bcl-2 were assessed by immunohistochemistry.

Results

We found that treatment of ChA21 caused a dose-dependent decrease of cell proliferation in vitro and a significant inhibition of tumor growth in vivo. ChA21 therapy led to a significant increase in the induction of apoptosis, and up-regulated the expression of Bax, while the expression of Bcl-2 was down-regulated.

Conclusion

These data suggest that ChA21 inhibits the growth and induces apoptosis of SK-OV-3 via regulating the balance between Bax and Bcl-2.


© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.